Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.
You may also be interested in...
Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles
Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.
Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co. CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.
Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.